optimerpharma.com

Optimer's core competence includes the development of innovative drugs for treating diseases that currently have no satisfactory therapy. These include antibiotics for drug-resistant bacterial infections, a cancer vaccine, and "disease-modifying" drugs for osteoarthritis. In the near term Optimer plans to bring in significant revenues through sponsored research, joint ventures, government grants, and license royalties. Optimer Pharmaceuticals, Inc. was founded and registered as a Delaware Corporation in 1998. The Company has licensed its technologies and therapeutic targets from The Scripps Research Institute and The Memorial Sloan-Kettering Cancer Center. These licenses form the core of Optimer's carbohydrate technologies. Under the leadership of its three founding scientists Michael Chang, Ph.D. (Optimer Pharmaceutical's President and CEO), Professor Chi-Huey Wong of Scripps Research Institute and Professor Samuel Danishefsky of Memorial Sloan-Kettering Cancer Center, the company has already assembled one of the best research and development teams in the field of carbohydrate technology.

This article uses content from http://www.AboutUs.org